Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

27.08 +0.67 (+2.54%)

Streaming Delayed Price Updated: 10:34 AM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50% ↗

December 21, 2023

Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in

Via Benzinga

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

December 20, 2023

From Roivant Sciences

Via GlobeNewswire

FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

December 20, 2023

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday.

Via Benzinga

Topics Stocks

Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease

December 14, 2023

From Roivant Sciences

Via GlobeNewswire

Analyst Ratings for Roivant Sciences ↗

December 12, 2023

Via Benzinga

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

November 28, 2023

From Roivant Sciences

Via GlobeNewswire

Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today? ↗

November 27, 2023

Roivant Sciences Ltd (NASDAQ: ROIV) and Priovant's Phase 2 study of oral brepocitinib in moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus (SLE)

Via Benzinga

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

November 27, 2023

From Roivant Sciences

Via GlobeNewswire

8 Analysts Have This to Say About Roivant Sciences ↗

November 14, 2023

Via Benzinga

Roivant Sciences Earnings Preview ↗

November 10, 2023

Via Benzinga

What 8 Analyst Ratings Have To Say About Roivant Sciences ↗

October 17, 2023

Via Benzinga

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update

November 13, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

November 10, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023

October 30, 2023

From Roivant Sciences

Via GlobeNewswire

Earnings Scheduled For November 13, 2023 ↗

November 13, 2023

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.

Via Benzinga

It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy ↗

October 24, 2023

The market's dour reaction to Roivant Sciences' latest deal doesn't add up.

Via The Motley Fool

FSR Stock Alert: What to Know as Fisker Drops Prices ↗

October 23, 2023

Fisker stock is on the move Monday as investors in FSR react to news of a price drop for one version of the company's Ocean EV.

Via InvestorPlace

PINS Stock Pops as Stifel Upgrades Pinterest ↗

October 23, 2023

Pinterest stock is getting a boost on Monday after a Stifel analyst upgraded PINS to a 'buy' rating and increasing its price target.

Via InvestorPlace

Why Is Roivant Sciences (ROIV) Stock Up Today? ↗

October 23, 2023

ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates.

Via InvestorPlace

Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space ↗

October 23, 2023

Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases.

Via Investor's Business Daily

Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal ↗

October 23, 2023

Roche Holding AG (OTC: RHHBY) inked a deal to acquire

Via Benzinga

Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket ↗

October 23, 2023

Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set...

Via Benzinga

Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

October 23, 2023

U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

October 23, 2023

From Roivant Sciences

Via GlobeNewswire

Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer

October 13, 2023

From Covant Therapeutics

Via GlobeNewswire

Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble. ↗

October 04, 2023

The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck.

Via Investor's Business Daily

3 No-Brainer Growth Stocks to Buy in October ↗

October 01, 2023

These three top mid-cap stocks could be poised for a long-tailed growth spurt.

Via The Motley Fool

Why Immunovant Stock Is Bolting Higher Today ↗

September 27, 2023

The company may have best-in-class autoimmune disease therapy under its roof.

Via The Motley Fool

Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

September 27, 2023

Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market...

Via Benzinga

Roivant Stock Price Outlook: Strong Pipeline Is A Catalyst ↗

September 27, 2023

Roivant Sciences has 12 drugs in its pipeline. The company’s Immunovant subsidiary reported strong results for its drug. Roivant is in talks with Roche to sell its Chron’s disease for $7 billion.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.